A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Summary

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Eligibility

Inclusion Criteria:

* Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria:

* This is not applicable to this study

Conditions3

Interventions2

Locations9 sites

Find trials near these locations

Related trials

• A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) — Dizal (Jiangsu) Pharmaceutical Co., Ltd.
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer — Oslo University Hospital
• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors — BeOne Medicines
• A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. — Australasian Leukaemia and Lymphoma Group
• Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib — Peter MacCallum Cancer Centre, Australia
• Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL — The First Affiliated Hospital of Soochow University
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Loxo Oncology, Inc.
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — BeOne Medicines

Browse More Trials